This Swiss Startup Just Raised Millions to Tackle a Major Fetal Surgery Risk

Jan de Vries · 2026-08-31

Zurich-based MedTech startup KOVE Medical just secured a $1.8 million funding round. That's right, they're moving forward with angel investor backing to develop something pretty remarkable—an implantable device aimed at reducing preterm birth risks after fetal surgery. It's a crucial step as they head toward First-in-Human studies. And honestly, it's coming at a time when European medical device companies are seeing serious momentum. CEO and co-founder Yannick Devaud put it simply: “Thanks to the team and our strong Angel investors team. Let's go tackle health issues at the beginning of life!” You can feel the energy there. This isn't just another funding announcement; it's about solving a real, heartbreaking problem. ### The Bigger Picture in European MedTech KOVE's raise is part of a much larger trend. In 2026 alone, we've seen some massive disclosed rounds across the continent. Think about it: - FineHeart, a French cardiac-device developer, pulled in a staggering $90 million in private capital and grants. - Ireland's Neurent Medical secured $67 million for minimally invasive treatments. - Dutch-US company Xeltis raised $22 million for vascular implants. - SamanTree Medical in Belgium got $21.5 million for surgical imaging. - Even closer to home, Switzerland's own Xsensio landed $6.5 million for wearable biochemical sensors. When you add it all up, that's over $210 million flowing into European MedTech innovation this year. It tells you the confidence investors have in this sector. ### So, What's KOVE Medical Actually Doing? Founded back in 2020 by Yannick Devaud and Kurt Ruffieux, KOVE spun out of research at the University of Zurich and its hospital. Their focus is laser-sharp: tackling a major complication in fetoscopy. Fetoscopy is that minimally invasive surgery doctors use to treat serious conditions in babies before they're even born. We're talking about life-altering issues like spina bifida, twin-to-twin transfusion syndrome, and congenital diaphragmatic hernia. The potential here is enormous—treating problems in utero can change entire life outcomes. But here's the catch. To perform these procedures, surgeons have to pass instruments through the uterine wall and the amniotic sac. That creates an opening. And that opening can weaken the fetal membrane, sometimes leading to leaks, premature rupture, and ultimately, preterm birth. It's a huge limitation. It means that even though the technology exists to help, the risk can sometimes outweigh the benefit. That's the wall KOVE is trying to break down. ### A Five-Minute Fix for a Persistent Problem KOVE's device is elegantly simple in concept. It's designed to close that surgical opening right after the fetal procedure is done. The implant goes in from inside the amniotic cavity and stabilizes the membrane right at the puncture site. The clever part? It's compatible with the entry ports surgeons are already using. No extra puncture needed. The company says positioning it takes less than five minutes. Think about that for a second. A five-minute step that could drastically reduce a major risk factor. The long-term goal is clear: give surgeons a reliable way to seal things up, making fetal surgery safer and more accessible for families who need it. This $1.8 million raise isn't just money in the bank. It's fuel for a mission that sits at the very heart of medical innovation—solving a concrete problem to give more babies a healthier start. In a landscape of big funding numbers, that's the human story that really matters.